Holen Sie sich die Stockscreener-App
67.68
0.59%
0.40
Handel nachbörslich:
67.00
-0.68
-1.00%
Schlusskurs vom Vortag:
$67.28
Offen:
$66.94
24-Stunden-Volumen:
1.17M
Relative Volume:
0.87
Marktkapitalisierung:
$5.71B
Einnahmen:
$4.04M
Nettoeinkommen (Verlust:
$-161.00M
KGV:
-32.50
EPS:
-2.0823
Netto-Cashflow:
$-132.48M
1W Leistung:
-1.73%
1M Leistung:
+5.27%
6M Leistung:
+57.21%
1J Leistung:
+236.55%
1-Tages-Spanne:
$65.89
$68.20
1-Wochen-Bereich:
$65.89
$70.62
52-Wochen-Spanne:
$19.47
$71.90
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
67.68 | 5.68B | 4.04M | -161.00M | -132.48M | -2.0823 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Wedbush | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
CGON Stock Up 60.8% in Six Months: Here's What You Need to Know - TradingView — Track All Markets
CG Oncology, Inc. Appoints New Chief Financial Officer Jim DeTore – Employment Agreement Details and Company Information - Minichart
Bull Bear: Will CG Oncology Inc outperform tech stocks2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
CG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer - TipRanks
CG Oncology appoints Jim DeTore as chief financial officer - Investing.com
CG Oncology appoints Jim DeTore as Chief Financial Officer - TradingView — Track All Markets
New CG Oncology (NASDAQ: CGON) CFO Jim DeTore gets $520k salary, equity - Stock Titan
CG Oncology (NASDAQ:CGON) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
SG Americas Securities Boosts Stake in CG Oncology - National Today
FY2027 EPS Estimates for CG Oncology Increased by Analyst - MarketBeat
Aug Big Picture: Is CG Oncology Inc stock a hidden gem2026 Macro Impact & AI Forecast Swing Trade Picks - baoquankhu1.vn
CG Oncology FY2029 EPS Forecast Increased by HC Wainwright - MarketBeat
Sivik Global Healthcare LLC Takes Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology stock hits all-time high at 69.41 USD By Investing.com - Investing.com Australia
Aug Sectors: What are the future prospects of CG Oncology Inc2026 Analyst Calls & Verified Technical Trade Signals - baoquankhu1.vn
CG Oncology stock hits all-time high at 69.41 USD - Investing.com
CG Oncology (NASDAQ:CGON) Hits New 52-Week High on Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for CG Oncology (NASDAQ:CGON) Stock - MarketBeat
Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharma - Barchart
H.C. Wainwright raises CG Oncology stock price target to $100 By Investing.com - Investing.com Canada
CGON Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Analyst Calls: What are the future prospects of CG Oncology IncDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
CEO Moves: Can CG Oncology Inc expand into new markets2026 Buyback Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade) - Seeking Alpha
CG Oncology stock hits all-time high at 60.01 USD By Investing.com - Investing.com Australia
CG Oncology Stock Surges on Fresh Institutional Backing - TipRanks
CGON PE Ratio & Valuation, Is CGON Overvalued - Intellectia AI
Aug Action: What is the target price for CG Oncology Inc stock2026 EndofYear Setup & Consistent Return Strategy Ideas - baoquankhu1.vn
Trade Recap: Can CG Oncology Inc expand into new markets - baoquankhu1.vn
Portfolio Recap: Is CG Oncology Inc impacted by rising ratesMarket Weekly Review & Expert Approved Momentum Ideas - baoquankhu1.vn
CG Oncology, Inc. $CGON Stake Lifted by JPMorgan Chase & Co. - MarketBeat
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know - AOL.com
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Downgraded by Wall Street Zen to Sell - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON): Are Analysts Optimistic? - 富途牛牛
Vanguard realignment reports 0% ownership in CG Oncology (CGON) - Stock Titan
UBS raises CG Oncology stock price target to $90 on trial outlook - Investing.com India
UBS Adjusts Price Target on CG Oncology to $90 From $60, Maintains Buy Rating - MarketScreener
UBS raises CG Oncology stock price target to $90 on trial outlook By Investing.com - za.investing.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Kynam Capital Cuts CG Oncology Holding: Q4 2025 Sale Details & ImpactNews and Statistics - IndexBox
This Biotech Stock Surged 135% but Just Saw a $44 Million Sell-Off. What Does This Mean for Investors? - bitget.com
CGON Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Quarterly Trades: Can CG Oncology Inc deliver consistent EPS growth2026 Key Highlights & Real-Time Price Movement Reports - baoquankhu1.vn
Why CG Oncology Stock Is Suddenly Losing Steam - TipRanks
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):